[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Benedetti-Panici P, Zullo MA, Plotti F, Manci N, Muzii L, Angioli R: Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy. Cancer; 2004 May 15;100(10):2110-7
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term bladder function in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy and type 3-4 radical hysterectomy.
  • BACKGROUND: The objective of the current study was to evaluate the incidence of long-term bladder dysfunction after type 3-4 radical hysterectomy in patients with locally advanced cervical carcinoma treated with neoadjuvant chemotherapy (NACT).
  • METHODS: A case-control study was conducted to evaluate the occurrence of long-term bladder dysfunction in 76 patients with International Federation of Gynecology and Obstetrics Stage IB-IIA (> 4 cm), Stage IIB, and Stage III cervical carcinoma who underwent type 3-4 radical hysterectomy after NACT.
  • The length of vagina removed was significantly greater among patients who had detrusor overactivity and mixed urinary incontinence compared with patients who had a normal diagnosis.
  • Three main disturbances were found: detrusor overactivity (21%), mixed urinary incontinence (24%), and de novo stress incontinence (21%).
  • Among patients who underwent type 4 radical hysterectomy, the extent of caudal resection of rectovaginal ligaments and vaginal tissue was found to be more strongly associated with bladder dysfunction than was the extent of lateral parametrial resection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hysterectomy. Urinary Bladder / physiopathology. Uterine Cervical Neoplasms / physiopathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Case-Control Studies. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prospective Studies. Time Factors. Urinary Incontinence, Stress / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139052.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Patel H, Joseph JV, Amodeo A, Kothari K: Laparoscopic salvage total pelvic exenteration: Is it possible post-chemo-radiotherapy? J Minim Access Surg; 2009 Oct;5(4):111-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for total pelvic exenteration in a male (removal of the bladder, prostate and rectum) and in a woman (removal bladder, uterus, vagina, ovaries and rectum) are rare.
  • The advanced stage generally dictates that the patient has some form of chemotherapy or radiotherapy, or a combination of two to shrink/debulk the tumour.
  • We report the first two cases of a salvage laparoscopic total pelvic exenteration in a male for rectal adenocarcinoma invading into the bladder and prostate, post-chemo-radiotherapy and in a woman for squamous cell carcinoma of cervix invading the bladder and rectum post-chemo-radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):907-18 [1115180.001]
  • [Cites] Surg Clin North Am. 1969 Apr;49(2):431-47 [4886910.001]
  • [Cites] Cancer. 1948 Jul;1(2):177-83 [18875031.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1023-30 [16890276.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):153-9 [16054678.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):624-9 [16014116.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):475-82 [15882172.001]
  • [Cites] Surg Oncol Clin N Am. 2005 Apr;14(2):289-300 [15817240.001]
  • [Cites] Semin Surg Oncol. 1999 Oct-Nov;17(3):161-7 [10504663.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):399-406 [9718168.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):130-5 [8995561.001]
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):207-10 [7896187.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):205-16 [3410348.001]
  • [Cites] Am J Obstet Gynecol. 1985 May 1;152(1):12-6 [2581447.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):934-43 [2586960.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):369-77 [14599868.001]
  • [Cites] Gynecol Oncol. 2002 Sep;86(3):311-5 [12217753.001]
  • [Cites] Semin Surg Oncol. 1999 Apr-May;16(3):236-41 [10225302.001]
  • [Cites] Gynecol Oncol. 1989 Oct;35(1):93-8 [2792911.001]
  • [Cites] Am J Obstet Gynecol. 1977 Dec 15;129(8):881-92 [930972.001]
  • [Cites] Gynecol Oncol. 1989 Jun;33(3):279-82 [2722049.001]
  • [Cites] Obstet Gynecol. 1989 Jun;73(6):1027-34 [2726106.001]
  • (PMID = 20407571.001).
  • [ISSN] 1998-3921
  • [Journal-full-title] Journal of minimal access surgery
  • [ISO-abbreviation] J Minim Access Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2843126
  • [Keywords] NOTNLM ; Laparoscopy / malignancy / pelvic exenteration
  •  go-up   go-down


3. Aggarwal S, Goel G, Banerji N, Khullar H: Sustained complete remission with taxane-based chemotherapy in stage IVB primary vaginal squamous cell carcinoma. Hematol Oncol Stem Cell Ther; 2009;2(2):362-3
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained complete remission with taxane-based chemotherapy in stage IVB primary vaginal squamous cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bridged Compounds / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Taxoids / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118062.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


Advertisement
4. Steed HL, Pearcey RG, Capstick V, Honore LH: Invasive squamous cell carcinoma of the vagina during pregnancy. Obstet Gynecol; 2002 Nov;100(5 Pt 2):1105-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive squamous cell carcinoma of the vagina during pregnancy.
  • BACKGROUND: Squamous cell carcinoma of the vagina in pregnancy is rare.
  • CASE: A 28-year-old primigravida with antepartum bleeding at 20 weeks' gestation was diagnosed with squamous cell carcinoma after biopsy of a vaginal mass.
  • The histology revealed an invasive grade 3 squamous cell carcinoma of large-cell, nonkeratinizing type.
  • The patient declined pregnancy termination and immediate radiation treatment.
  • She continued to have episodes of vaginal bleeding and was admitted at 30 weeks' gestation.
  • A decision was made in consultation with the neonatal unit to deliver her at 32 weeks' gestation.
  • After corticosteroid treatment, she was delivered by cesarean delivery.
  • Postoperatively, she received external beam radiation and brachytherapy and concurrent cisplatin chemotherapy.
  • She is disease free 3 years from her original diagnosis.
  • CONCLUSION: This case emphasizes the importance of a thorough pelvic examination to assess the vaginal walls and cervix at the first prenatal visit and with any antepartum bleeding episode.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Pregnancy Complications, Neoplastic / pathology. Pregnancy Complications, Neoplastic / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adult. Brachytherapy. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Pregnancy. Radiotherapy Dosage


5. Nashiro T, Yagi C, Hirakawa M, Inamine M, Nagai Y, Sakumoto K, Tamaki W, Ogawa K, Toita T, Aoki Y: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. Int J Clin Oncol; 2008 Aug;13(4):335-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review.
  • BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT).
  • METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital.
  • All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy.
  • Then two of the six patients underwent intracavitary vaginal brachy-therapy.
  • Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy.
  • One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months.
  • One patient with stage IVA developed a vesicovaginal fistula during CCRT.
  • Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system.
  • CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Middle Aged. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1982 Oct;14(2):154-63 [7129211.001]
  • [Cites] Gynecol Oncol. 2001 Jun;81(3):360-5 [11371123.001]
  • [Cites] Br J Obstet Gynaecol. 1981 Nov;88(11):1145-50 [7295606.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):37-45 [10219792.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):892-7 [3967181.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):138-47 [15850914.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Baillieres Clin Obstet Gynaecol. 1987 Jun;1(2):319-29 [3319337.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Gynecol Oncol. 1991 Dec;43(3):233-6 [1752493.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):435-43 [7705681.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):758-70 [11241244.001]
  • [Cites] Gynecol Oncol. 1987 May;27(1):110-5 [3570044.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S29-42 [17161165.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):1033-40 [9731908.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):110-7 [14764038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):891-905 [8751398.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):901-6 [3141319.001]
  • (PMID = 18704634.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


6. Myriokefalitaki E, Iavazzo C, Vorgias G, Akrivos T: A two eterochronous primary gynaecological malignancies of different origin. Bratisl Lek Listy; 2009;110(11):726-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE: A 65-year-old para-2, white obese female, presented in our department 4 years ago, due to a single event of vaginal spotting.
  • Curettage revealed an endometrial cancer.
  • No additional therapy was given.
  • Although, recurrence on vaginal cuff was possible, the biopsies of anterior vaginal wall showed a poorly differentiated squamous cell carcinoma of the vagina.
  • The patient was classified as stage II vaginal carcinoma and underwent complete radiotherapy and chemotherapy.
  • CONCLUSION: This case indicates that female genital carcinomas of different histological origins may occur with minimal time-interval, even in the absence of known predisposing factors like previous chemo-radiotherapy, HPV infection or diethylstilbestrol exposure.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Squamous Cell / diagnosis. Endometrial Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Vaginal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120445.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


7. Adewuyi SA, Shittu OS, Rafindadi AH, Zayyan MS, Samaila MO, Oguntayo AO: Cisplatin chemotherapy for haemostasis in bleeding cervical cancer: experience from a resource-poor setting. Niger Postgrad Med J; 2010 Jun;17(2):122-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin chemotherapy for haemostasis in bleeding cervical cancer: experience from a resource-poor setting.
  • BACKGROUND: Cervical cancer is the commonest cancer in northern Nigeria.
  • The number of patients requiring radiotherapy for various malignancies is beyond the available facilities and expertise leading to long waiting time and disease progression with its attendant sequelae.
  • This is the basis of using other orthodox treatment modalities as first line.
  • PATIENTS AND METHODS: Between January 2006 and December 2007, 116 patients with histologically confirmed cervical cancer with vaginal bleeding as the predominant symptom were treated.
  • Patients were interviewed with a structured pro forma on a 3-weekly basis during chemotherapy schedules to assess and evaluate per vaginal bleeding and discharge.
  • Dose of chemotherapy was 70 mg/m² every 3 weeks.
  • 62 patients were having per vagina bleeding for more than 6 months before commencement of chemotherapy (range 1-60 months).
  • 49 patients had blood transfusion before chemotherapy, average of 2.7 pints of blood transfused per patient.
  • Squamous cell carcinoma is the commonest histology type followed by adenocarcinoma with 95 and 16 patients respectively.
  • 81 patients had complete cessation of per vagina bleeding with 69 having complete cessation on or before 4th course of chemotherapy (9th week) and complete cessation of per vagina discharges was seen in 52 patients.
  • 115 patients had a performance status KPS of below 80 prior to chemotherapy, and after completing 6 cycles, 100 patients had KPS of 80 and above.
  • CONCLUSION: In resource-poor setting, Cisplatin based chemotherapy can be used by medical, gynaecological oncologists and general practitioners to control vaginal bleeding and improve the quality of life of patients pending radiotherapy.
  • For optimal treatment with chemoradiotherapy, government and non-governmental agencies must do all it takes to remedy the problems of shortage of resources.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Hemostasis / drug effects. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Hemorrhage / drug therapy. Hemorrhage / etiology. Humans. Karnofsky Performance Status. Middle Aged. Neoplasm Staging. Nigeria


8. Takekuma M, Hirashima Y, Takahashi N, Yamamichi G, Furukawa N, Yamada Y, Takakuwa R, Ito I: A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin. Anticancer Drugs; 2006 Jul;17(6):715-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of glassy cell carcinoma of the uterine cervix that responded to neoadjuvant chemotherapy with paclitaxel and carboplatin.
  • Glassy cell carcinoma of the uterine cervix is a rare tumor, and has a poor prognosis because of its aggressive clinical behavior and resistance to radiotherapy and chemotherapy.
  • We report a case of bulky glassy cell carcinoma of the uterine cervix that effectively responded to paclitaxel and carboplatin in a neoadjuvant setting.
  • The patient was a 30-year-old woman who became aware of vaginal bleeding and was referred to our hospital because of a cancerous tumor of the uterine cervix.
  • Physical examination showed the cervical tumor to be approximately 8 cm in diameter with no involvement of the parametrium or vagina.
  • The biopsy results suggested a diagnosis of glassy cell carcinoma.
  • The final diagnosis was glassy cell carcinoma of the uterine cervix, stage 1b2.
  • Neoadjuvant chemotherapy with paclitaxel and carboplatin was administered for downstaging.
  • The response rate was 67.9% (partial response) under magnetic resonance imaging, and elevated serum cancer-related antigen 125 (119 U/ml) and squamous cancer cell antigen (34 ng/ml) were reduced to 34 U/ml and 3.3 ng/ml, respectively.
  • Following neoadjuvant chemotherapy, she underwent radical hysterectomy and adjuvant chemotherapy with the same regimen.
  • We speculate that glassy cell carcinoma is a sensitive tumor to paclitaxel and carboplatin.
  • Further evaluation concerning diagnosis and treatment, however, is needed to improve the prognosis of patients with glassy cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Paclitaxel / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917218.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Lv L, Sun Y, Liu H, Lou J, Peng Z: Neoadjuvant chemotherapy followed by radical surgery and reconstruction of the vagina in a patient with stage II primary vaginal squamous carcinoma. J Obstet Gynaecol Res; 2010 Dec;36(6):1245-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by radical surgery and reconstruction of the vagina in a patient with stage II primary vaginal squamous carcinoma.
  • Primary vaginal carcinoma is a rare gynecologic cancer.
  • Radiotherapy is the standard treatment for patients affected by International Federation of Gynecology and Obstetrics stage II vaginal cancer.
  • Neoadjuvant chemotherapy followed by radical surgery has been shown to be a valid therapeutic strategy in patients with cervical cancer; however, there is little information concerning the feasibility of neoadjuvant chemotherapy followed by radical surgery in patients with invasive vaginal carcinoma.
  • We report the first case of stage II vaginal carcinoma with neoadjuvant chemotherapy followed by radical surgery combined with vaginal reconstruction using bilateral pudendal thigh fasciocutaneous flaps.
  • The patient was free of disease with a satisfactory sexual life after 30 months.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Reconstructive Surgical Procedures. Vaginal Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Neoadjuvant Therapy. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal of Obstetrics and Gynaecology Research © 2010 Japan Society of Obstetrics and Gynecology.
  • (PMID = 20731765.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


10. Lilic V, Lilic G, Filipovic S, Visnjic M, Zivadinovic R: Primary carcinoma of the vagina. J BUON; 2010 Apr-Jun;15(2):241-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoma of the vagina.
  • In this paper we reviewed the risk factors for primary carcinoma of the vagina (PCV), diagnostic and therapeutic modalities, and principles leading to rational decision-making in the individualized management of vaginal carcinoma patients.
  • Histopathologically, most common are squamous cell carcinoma (80-90%) and adenocarcinoma (4-10%).
  • The leading risk factor for vaginal intraepithelial neoplasia (VAIN) and subsequent squamous cell vaginal carcinoma is long-lasting infection with human papillomavirus (HPV) type 16.
  • Prognosis of the disease depends on several factors, the most important of which are age, histologic type, and tumor stage.
  • Due to its being a rare entity, there are still controversies as to the most optimal treatment.
  • Individualized treatment approaches have been increasingly used.
  • In most centres, standard treatment for this cancer is radiotherapy.
  • Some reports have shown that surgery might also be an option, while in some centres radiation is supplemented by cisplatin-based chemotherapy.
  • The supposed advantage of radiotherapy is the preservation of the anatomy and function of the vagina.
  • We believe that there are certain psychologic benefits with the preservation of the vagina, regardless of its function.
  • However, preservation of the vaginal function after treatment of invasive vaginal cancer is a rare phenomenon, both in the literature and from our own experience.
  • [MeSH-major] Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / epidemiology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Incidence. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Squamous Cell / pathology. Neoplasms, Squamous Cell / surgery. Prognosis. Risk Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20658716.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 45
  •  go-up   go-down


11. Dalrymple JL, Russell AH, Lee SW, Scudder SA, Leiserowitz GS, Kinney WK, Smith LH: Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer; 2004 Jan-Feb;14(1):110-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation for primary invasive squamous carcinoma of the vagina.
  • OBJECTIVE: To report outcomes for patients with primary, invasive, squamous carcinoma of the vagina treated with chemoradiation.
  • METHODS: Between 1986 and 1996, 14 patients were treated with primary therapy consisting of synchronous radiation and chemotherapy.
  • Chemotherapy consisted of 5-fluorouracil alone (seven patients), or with cisplatin (six patients) or mitomycin-C (one patient).
  • Four patients died of intercurrent illness (46, 92, 104, 109 months) and nine are alive and cancer-free 74-168 months after treatment (median 100 months).
  • CONCLUSIONS: Radiation with synchronous chemotherapy is an effective treatment for squamous carcinoma of the vagina.
  • Cancer control outcomes compare favorably with previously published results employing higher dose radiation as monotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Neoplasm Recurrence, Local / mortality. Vaginal Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. California / epidemiology. Combined Modality Therapy. Female. Humans. Longitudinal Studies. Medical Records. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Registries. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14764038.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Macchia G, Ferrandina G, Legge F, Deodato F, Ruggieri V, Lorusso D, Padula GD, Valentini V, Cellini N, Scambia G, Morganti AG: Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase II study (ESTER-1). Am J Clin Oncol; 2010 Dec;33(6):577-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase II study (ESTER-1).
  • INTRODUCTION: The aim of this phase II study was to evaluate response and toxicity of a prolonged chemoradiation regimen in patients with locally advanced cervical cancer.
  • PATIENTS AND METHODS: Three cycles of concomitant chemotherapy were used with cisplatin (20 mg/m², 2-hour intravenous infusion, days 1-4) and 5-fluorouracil (1000 mg/m², 24-hour continuous intravenous infusion, days 1-4) administered at weeks 1, 5, and 9 of radiotherapy.
  • The CTV was defined as follows: gross tumor volume, upper half of the vagina (if not involved) or the whole vagina (if clinically involved), uterus, obturator nodes, external iliac nodes, internal iliac nodes, and the presacral nodes (cranial to S2).
  • The prescribed dose to the PTV was 50 Gy, 2 Gy/fraction (ICRU 62) delivered in 25 fractions with a 2-week break at 20Gy and 40 Gy (split-course technique).
  • All patients completed the prescribed dose of chemoradiation and were evaluated 4 weeks after the end of treatment.
  • About 32% of patients experienced grade 3 to 4 toxicity, in particular, grade 3 or 4 hematological toxicity was observed in 7 patients and 1 patient developed grade 3 genitourinary toxicity.
  • No patients developed grade 3 gastrointestinal toxicity or skin toxicity.
  • Seven patients (28%) showed a complete response (CR) to treatment, and 7 patients (28%) showed microscopic residual disease (μPR), totaling 14 patients (56%) complete/partial microscopic responses.
  • Perioperative morbidity was higher than reported in historical controls especially in terms of tissue fibrosis (64%) and perioperative urinary toxicity (14%).
  • CONCLUSION: A prolonged treatment with more chemotherapy courses does not improve tumor response and increases the risk of perioperative complication.
  • This treatment regimen, considering the low incidence of acute gastrointestinal toxicity, might be tested in the adjuvant setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brachytherapy / methods. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Kaplan-Meier Estimate. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging. Preoperative Care. Prospective Studies. Radiotherapy Dosage. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023568.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Wei LH, Huang CY, Cheng SP, Chen CA, Hsieh CY: Carcinosarcoma of ovary associated with previous radiotherapy. Int J Gynecol Cancer; 2001 Jan-Feb;11(1):81-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been sporadic case reports of the development of carcinosarcomas of the cervix, vagina, and extragenital areas, but not of the ovary, after previous pelvic irradiation.
  • The patient was treated by optimal cytoreduction, followed by chemotherapy with adriamycin and cisplatin.
  • However, acute hepatitis caused by reactivation of hepatitis B virus infection developed just before the fifth course of chemotherapy.
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Fatal Outcome. Female. Hepatitis B / chemically induced. Hepatitis B / mortality. Humans. Uterine Cervical Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11285039.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Gabriele A, Gaudiano L: Primary malignant lymphoma of the cervix. A case report. J Reprod Med; 2003 Nov;48(11):899-901
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A review of the literature suggests that 1 in 175 extranodal lymphomas in women is likely to originate in the vagina, uterus or cervix.
  • Often the diagnosis of primary lymphoma is not established until after an operation has been performed.
  • Postsurgical treatment is usually chemotherapy alone or followed by radiotherapy.
  • Six courses of chemotherapy were administered in an adjuvant setting.
  • Twenty-seven months (April 2003) after the diagnosis the patient was alive and without signs of recurrent disease.
  • CONCLUSION: Awareness of this rare clinical entity is important because these tumors can present at any age and may mimic squamous cell carcinoma of the cervix clinically and histologically.
  • Extent of disease, size of primary lesion and type of lymphoma are significant prognostic features.
  • Standard postsurgical treatment has not yet been established.
  • [MeSH-major] Lymphoma / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Hysterectomy. Uterine Hemorrhage / etiology


15. Strauss HG, Kuhnt T, Laban C, Puschmann D, Pigorsch S, Dunst J, Koelbl H, Haensgen G: Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlenther Onkol; 2002 Jul;178(7):378-85
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
  • BACKGROUND: In 1999, five randomized studies demonstrated that chemoradiation with cisplatin and low-dose rate (LDR) brachytherapy has a benefit in locally advanced cervical cancer and for surgically treated patients in high-risk situations.
  • We evaluated the safety and efficacy of concomitant chemoradiation with cisplatin and high-dose rate (HDR) brachytherapy in patients with cervical cancer.
  • PATIENTS AND METHODS: 27 patients were included in our phase-II trial: 13 locally advanced cases (group A) and 14 adjuvant-therapy patients in high-risk situations (group B).
  • A definitive radiotherapy was performed with 25 fractions of external beam therapy (1.8 Gy per fraction/middle shielded after eleven fractions).
  • Brachytherapy was delivered at HDR schedules with 7 Gy in point A per fraction (total dose 35 Gy) in FIGO Stages IIB-IIIB.
  • The total dose of external and brachytherapy was 70 Gy in point A and 52-54 Gy in point B.
  • Adjuvant radiotherapy was performed with external beam radiotherapy of the pelvis with 1.8 Gy single-dose up to 50.4 Gy.
  • Brachytherapy was delivered at HDR schedules with two fractions of 5 Gy only in patients with tumor-positive margins or tumor involvement of the upper vagina.
  • The chemotherapeutic treatment schedule provided six courses of cisplatin 40 mg/m2 weekly recommended in the randomized studies GOG-120 and -123.
  • RESULTS: A total of 18/27 patients (66.7%) completed all six courses of chemotherapy.
  • Discontinuation of radiotherapy due to therapy-related morbidity was not necessary in the whole study group.
  • 12/13 patients (92.3%) with IIB-IVA cervical cancer showed a complete response (CR).
  • CONCLUSION: Concomitant chemoradiation with cisplatin 40 mg/m2 weekly x 6 using HDR brachytherapy represents a promising treatment of cervical cancer with an acceptable toxicity.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12163992.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Senkus E, Konefka T, Nowaczyk M, Jassem J: Second lower genital tract squamous cell carcinoma following cervical cancer. A clinical study of 46 patients. Acta Obstet Gynecol Scand; 2000 Sep;79(9):765-70
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second lower genital tract squamous cell carcinoma following cervical cancer. A clinical study of 46 patients.
  • BACKGROUND: Patients after treatment for cervical cancer have increased risk of developing second squamous cell malignancy of the lower genital tract.
  • MATERIAL AND METHODS: A retrospective study of 46 patients with second lower genital tract epidermoid cancers following previous treatment for invasive cervical carcinoma.
  • RESULTS: Patient age at diagnosis of cervical cancer was 27 to 68 years (median 44 years) and at diagnosis of the second malignancy - 43 to 72 years (median 63 years).
  • Time span between metachronous malignancies ranged from 66 to 406 months (median 206 months).
  • In 32 cases (70%) second lesion was located in the vagina and in 14 (30%) - in the vulva.
  • Treatment of second cancer consisted of surgery in 12 patients (26%), radiotherapy in 23 (50%), combined surgery and radiotherapy--in five (11%), chemotherapy in four (9%) and surgery plus chemotherapy - in one case.
  • Median survival was 52 months and five-year survival from the diagnosis of second malignancy - 47.5%.
  • CONCLUSION: Treatment outcome in patients with second lower genital tract carcinoma is unsatisfactory due to poor feasibility of another definite treatment after previous radical surgery and/or radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Uterine Cervical Neoplasms / pathology. Vaginal Neoplasms / mortality. Vulvar Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Palliative Care. Poland / epidemiology. Retrospective Studies. Survival Analysis. Treatment Outcome


17. Negro CL, De Stefanis P, Bosio A, Bisconti A, De Maria C, Charchedi M, Buffardi A, Rolle L, Fontana D: [Transvaginal repair of neobladder vaginal fistula]. Urologia; 2010 Jan-Mar;77 Suppl 16:11-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transvaginal repair of neobladder vaginal fistula].
  • INTRODUCTION: Neobladder vaginal fistula is a known complication after cystectomy and orthotopic neobladder in women.
  • We present our personal experience with a case of neobladder vaginal fistula.
  • METHODS: A fifty-year old woman affected by T2G3 bladder cancer underwent radical cystectomy and orthotopic neobladder in December 2007.
  • Definitive pathological examination revealed pT3aN0G3 urothelial cancer with squamous aspects.
  • Two cycles of neoadjuvant chemotherapy were administered before cystectomy.
  • Three weeks after cystectomy, a retrograde cystography revealed a fistula between vagina and neobladder.
  • CONCLUSION: The development of a neobladder-vaginal fistula is a significant, even if infrequent, complication after cystectomy.
  • In our case, we performed a transvaginal approach without tissue interposition, with good results.
  • Such procedure is easy and effective and, in our opinion, can be tempted as first line surgical treatment.
  • [MeSH-major] Ileal Diseases / surgery. Intestinal Fistula / surgery. Postoperative Complications / surgery. Urinary Diversion. Vaginal Fistula / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / surgery. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Hysterectomy, Vaginal. Middle Aged. Radiography. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21104654.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Hoopmann M, Valter M, Kurbacher C, Possover M, Mallmann PK: Chemopersistent early recurrence in the perineal tear scar of an intrapartally diagnosed cervical cancer. Gynecol Oncol; 2003 Oct;91(1):272-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopersistent early recurrence in the perineal tear scar of an intrapartally diagnosed cervical cancer.
  • BACKGROUND: Cervical cancer is the most frequent cancer occurring in pregnancy.
  • Apart from some general recommendations, there is no standardized consensus for the management of this cancer during pregnancy.
  • Individual case reports do exist on intrapartal cancer diagnosis and risks.
  • CASE: We describe the case of an early recurrence in the perineal tear scar of an intrapartally diagnosed cervical cancer, which had developed despite combined neoadjuvant and adjuvant chemotherapy.
  • CONCLUSIONS: Although iatrogenic tumor cell spreading in the vagina is rare, this oncological risk is easy to avoid.
  • It should be considered in the peripartal management of patients suffering from cervical cancer.
  • Our case report underlines the limits of chemotherapy in the treatment of tumor residue and points out the problem of cervical cancer cell spreading during invasive procedures.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Neoplasm Recurrence, Local / pathology. Perineum / injuries. Perineum / pathology. Pregnancy Complications, Neoplastic / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Neoadjuvant Therapy. Pregnancy


19. Silver SA, Tavassoli FA: Glomus tumor arising in a mature teratoma of the ovary: report of a case simulating a metastasis from cervical squamous carcinoma. Arch Pathol Lab Med; 2000 Sep;124(9):1373-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomus tumor arising in a mature teratoma of the ovary: report of a case simulating a metastasis from cervical squamous carcinoma.
  • This lesion represented an incidental finding in a 43-year-old woman who underwent bilateral salpingo-oophorectomy at the time of detection of locally recurrent squamous carcinoma of the cervix.
  • The glomus tumor was initially interpreted as a metastasis due to its superficial morphologic resemblance to the recurrent carcinoma in the vagina.
  • The diagnosis was supported by immunohistochemistry and ultrastructural examination.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Glomus Tumor / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology. Teratoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy. Immunohistochemistry. Lymph Node Excision. Microscopy, Electron. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Ovariectomy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / surgery

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10975942.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


20. Frank SJ, Deavers MT, Jhingran A, Bodurka DC, Eifel PJ: Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. Gynecol Oncol; 2007 May;105(2):470-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure.
  • OBJECTIVE: Primary non-diethylstilbestrol (DES)-associated adenocarcinoma of the vagina (NDAV) is a rare entity that has not been well described.
  • METHODS: The tumors of all patients treated with definitive radiation therapy for NDAV between 1970 and 2000 were centrally reviewed.
  • Data regarding patient, tumor, and treatment characteristics were abstracted from the hospital records of each patient.
  • Survival rates were calculated and outcomes of patients with NDAV were compared with those of patients with squamous cell carcinoma (SCC) of the vagina treated similarly over the same period.
  • RESULTS: Twenty-six patients with a median age of 54 years had primary NDAV confirmed by central pathologic review.
  • Twenty patients (77%) were treated with external-beam radiation therapy (EBRT) followed by brachytherapy, and six patients (23%) were treated with EBRT alone.
  • At 5 years, 39% of patients with NDAV and 15% with SCC had developed distant metastasis (p<0.01).
  • CONCLUSIONS: Primary NDAV is a rare disease with a poor prognosis.
  • Patients with this disease have significantly worse outcomes than do patients with SCC, and chemotherapy or novel systemic biologic agents may be needed to achieve higher cure rates.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / pathology. Diethylstilbestrol / adverse effects. Vaginal Neoplasms / etiology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17292459.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


21. Hainsworth JD, Burris HA 3rd, Meluch AA, Baker MN, Morrissey LH, Greco FA: Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer; 2001 Aug 1;92(3):642-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial.
  • BACKGROUND: The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of the combination of paclitaxel, carboplatin, and long-term continuous infusion 5-fluorouracil (5-FU) in the treatment of advanced squamous carcinomas of various primary sites.
  • METHODS: Patients were eligible for this trial if they had metastatic squamous carcinoma at any site except the lung.
  • In addition, patients with locally advanced squamous carcinoma of the head and neck were eligible, if they were considered unlikely to be cured with combined modality therapy.
  • Sixty patients entered this trial between February 1995 and March 1999; 12 patients (20%) had received 1 previous chemotherapy regimen, whereas 48 patients (80%) were previously untreated.
  • All patients received the following regimen: paclitaxel 200 mg/m(2), 1-hour intravenous infusion, Days 1 and 22; carboplatin area under the concentration-time curve (AUC) 6.0 intravenously, Days 1 and 22; 5-FU 225 mg/m(2)/day, by 24-hour continuous intravenous infusion, Days 1-35.
  • Treatment courses were repeated at 6-week intervals; responding patients continued treatment for a maximum of 4 courses (24 weeks).
  • Twelve patients (22%) remain progression free from 7 to 63 months (median, 35 months) after completion of therapy.
  • Complete responses were observed in squamous carcinomas from various primary sites including head and neck, esophagus, cervix, vagina, anus, and unknown primary.
  • The most frequent Grade 3/4 toxicities observed with this 3-drug regimen included leukopenia (48%), diarrhea (17%), mucositis (28%), and portacath-related events (13%).
  • CONCLUSIONS: The combination of paclitaxel, carboplatin, and long-term infusional 5-FU is feasible, well tolerated, and highly efficacious in patients with advanced squamous carcinomas of various primary sites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11505410.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Goker BO, Bese T, Ilvan S, Yilmaz E, Demirkiran F: A case with multiple gynecological malignancies. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):372-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with cervical non-Hodgkin lymphoma was treated with chemotherapy.
  • Fourteen months after the diagnosis of the lymphoma, an endometrial adenocarcinoma was detected as a secondary malignant tumor.
  • Approximately 7 years after the diagnosis of endometrial cancer, vaginal invasive squamous cell carcinoma was diagnosed as the third primary malignancy, and a second-line palliative radiotherapy was applied.
  • Seven months after the last radiotherapy, postradiational sarcoma in the vagina was diagnosed.
  • Congenital and acquired immune system disorders, viral oncogenes, and various human leukocyte antigen (HLA) types were investigated.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymphoma, Non-Hodgkin / drug therapy. Neoplasms, Multiple Primary / pathology. Sarcoma / pathology. Uterine Cervical Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823128.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Jin B, Pickens A, Shah MB, Turrisi A, Saleh H: Primary large cell neuroendocrine carcinoma of the vagina: cytomorphology of previously unreported case. Diagn Cytopathol; 2010 Dec;38(12):925-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary large cell neuroendocrine carcinoma of the vagina: cytomorphology of previously unreported case.
  • Squamous carcinoma is the most common malignancy of the vagina.
  • Other malignancies include adenocarcinoma, melanoma, lymphoma, and very rarely, neuroendocrine carcinoma/small-cell carcinoma.
  • Large cell neuroendocrine carcinoma (LCNEC) has not been reported in this location.
  • In this report, we describe a case of LCNEC of the vagina, which is believed to be the first case to date in the English literature.
  • The patient is a 53-year old gravida 3, para 2, African-American woman who had a 4 month history of severe pelvic pain and difficulty voiding and was found to have a firm plate-like mass on the anterior vaginal wall.
  • Thin prep of vaginal swap was interpreted as atypical glandular cells; however, the biopsies showed a large cell neuroendocrine carcinoma which was confirmed by diffuse strong immunoreactivity to AE1/3, CAM5.2, CK7, and CD56 in the tumor cells.
  • Subsequent clinical workup showed that the patient also had numerous metastatic nodules in the bilateral lungs and a vaginal-urethral fistula caused by the tumor.
  • The patient underwent palliative radiation of pelvis for local pain control and then chemotherapy.
  • Although the vaginal tumor increased in size even after radiation, her symptoms were under control and she was doing well for a short period of time.
  • The patient is still alive but developed brain metastasis a year later after initial diagnosis.
  • Despite its rarity, large cell neuroendocrine cell carcinoma should be included in the differential diagnosis when cytomorphology shows features suggestive of neuroendocrine differentiation.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Antigens, CD56 / metabolism. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20222107.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


24. Luo LM, Huang HF, Pan LY, Shen K, Wu M, Xu L: [Clinical analysis of 42 cases of primary malignant tumor in vagina]. Zhonghua Fu Chan Ke Za Zhi; 2008 Dec;43(12):923-7
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 42 cases of primary malignant tumor in vagina].
  • OBJECTIVE: To analyze the clinical characters, treatment and prognosis of primary malignant tumor in vagina.
  • METHODS: A retrospective analysis of 42 patients diagnosed with primary malignant tumor in vagina in Peking Union Medical College Hospital (PUMCH) between Jan 1984 and Aug 2006 was performed.
  • Thirteen cases were squamous carcinoma, 13 cases were malignant melanoma, 8 cases were adenocarcinoma, 3 cases were yolk sac tumor and 5 cases were other types.
  • The majority of patients were treated with surgery combined with radiotherapy and chemotherapy.
  • The longest follow up was 10 years, with the median time of 2 years.
  • The 2-year survival rate of patients with squamous carcinoma was 46.8%, malignant melanoma 72.9%, adenocarcinoma 20.0% and patients with yolk sac tumor were all alive tumor-free after 6 - 10 years' follow up.
  • CONCLUSIONS: The prognosis of primary malignant tumor in vagina is affected by clinical stage and histological type.
  • As to malignant melanoma, radical surgery combined with chemotherapy and immunotherapy produce good effects.
  • Patients with yolk sac tumor can be cured only with chemotherapy.
  • As to other types, more treatment experiences are needed.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Infant. Melanoma / mortality. Melanoma / pathology. Melanoma / surgery. Melanoma / therapy. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Vagina / pathology. Vagina / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19134332.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Gadducci A, Cionini L, Romanini A, Fanucchi A, Genazzani AR: Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol; 2006 Dec;60(3):227-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer.
  • During the last decades there has been a continuing evolution in the surgical approach of squamous cell carcinoma of the vulva that has been traditionally treated with radical vulvectomy and bilateral inguinal-femoral lymphadenectomy.
  • Modifications of the surgical technique of deep femoral lymphadenectomy and the mapping of sentinel node can offer new interesting therapeutic perspectives.
  • Locally advanced squamous cell carcinoma of the vulva has been long surgically treated with en-block radical vulvectomy and bilateral inguinal-femoral lymphadenectomy plus partial resection of urethra, vagina or anum, or by exenteration, with severe postsurgical complications, poor quality of life, and unsatisfactory survival rates.
  • 5-Fluorouracil [5-FU] or 5-FU- and cisplatin-based chemotherapy concurrent with irradiation followed by tailored surgery represents an attractive therapeutic option for advanced disease, planned to avoid such ultra-radical surgical procedures and, hopefully, to improve patient outcome.
  • Chemotherapy has also been used in neoadjuvant setting, with contrasting and generally unsatisfactory results, and in palliative treatment of patients with distant metastases.
  • Surgery is the primary treatment also for vulvar malignancies other than squamous cell carcinoma, whereas the clinical usefulness of adjuvant irradiation or chemotherapy is still to be defined.
  • Primary chemoradiation can be also used for advanced carcinoma of the Bartholin gland or for advanced adenocarcinoma associated with extramammary Paget's disease.
  • The drugs used for chemotherapy of metastatic melanomas or sarcomas of the vulva are the same employed for the melanomas or sarcomas developed in other sites.
  • [MeSH-major] Vulvar Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Neoplasm Metastasis. Recurrence

  • Genetic Alliance. consumer health - Vulvar cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945551.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 167
  •  go-up   go-down


26. Salom EM, Penalver M: Recurrent vulvar cancer. Curr Treat Options Oncol; 2002 Apr;3(2):143-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent vulvar cancer.
  • Recurrent vulvar cancer occurs in an average of 24% of cases after primary treatment after surgery with or without radiation.
  • The relatively few primary vulvar cancers, combined with the low proportion of recurrences, has made it difficult to perform randomized studies to document the most appropriate therapeutic modalities.
  • Traditionally, the most accepted treatment of vulvar cancer has been and continues to be surgery.
  • Recently, radiation and chemotherapy have been combined with very encouraging results.
  • The therapeutic modality used depends on the location and extent of the recurrence.
  • Lateralized local vulvar recurrences treated with a wide radical local excision with inguinal lymphadectomy results in an excellent cure rate of 70%.
  • With a central pelvic recurrence with antecedent radiotherapy involving the urethra, upper vagina, and rectum, total pelvic exenteration is indicated in a select group of patients with curative intent.
  • Prospective and retrospective studies have shown excellent results using radiation or chemoradiation with wide radical local excision in patients with locally advanced disease in whom adequate resection margins are difficult to achieve (with a central lesion requiring exenteration) or with debilitating medical conditions that preclude surgery.
  • Regional recurrences to the inguinal and pelvic lymph nodes have been shown to have a poor prognosis with a high mortality rate.
  • We recommend that inguinal recurrences without prior radiation therapy undergo excision followed by radiotherapy with chemosensitization.
  • With pelvic recurrences, we recommended chemoradiation as the treatment modality.
  • In the subset of patients with distant metastasis, chemotherapy may be offered; however, few studies have been performed to advocate any single combination.
  • The literature supports the use of 5-fluorouracil or cisplatin as single agents or in combination to have sensitivity against squamous cells.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Vulvar cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1990 Sep;163(3):1007-15 [2403127.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1943-9 [6478428.001]
  • [Cites] Am J Obstet Gynecol. 1999 Jul;181(1):91-8 [10411801.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1193-7 [10725631.001]
  • [Cites] Am J Obstet Gynecol. 1990 May;162(5):1278-82 [2339729.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):202-5 [7622106.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):263-7 [2504651.001]
  • [Cites] Acta Radiol Oncol. 1984;23(5):345-8 [6095605.001]
  • [Cites] Am J Obstet Gynecol. 1992 Nov;167(5):1383-9 [1442996.001]
  • [Cites] Gynecol Oncol. 1993 Feb;48(2):189-95 [8428690.001]
  • [Cites] Eur J Gynaecol Oncol. 1993;14(4):318-22 [8344328.001]
  • [Cites] Am J Obstet Gynecol. 1998 Aug;179(2):343-8 [9731836.001]
  • [Cites] Obstet Gynecol. 1990 Jun;75(6):1001-5 [2342725.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2835-8 [1451064.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Gynecol Oncol. 1986 Feb;23(2):192-8 [3943761.001]
  • [Cites] Gynecol Oncol. 1996 Jun;61(3):321-7 [8641609.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):51-6 [7557615.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):309-14 [2227541.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):403-26 [3549645.001]
  • [Cites] Am J Obstet Gynecol. 1982 Jun 1;143(3):340-51 [7081350.001]
  • [Cites] Gynecol Oncol. 1991 Sep;42(3):197-201 [1955180.001]
  • [Cites] Am J Clin Oncol. 1987 Apr;10(2):171-81 [3565317.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):14-20 [1427394.001]
  • (PMID = 12057077.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 27
  •  go-up   go-down


27. Coulter J, Gleeson N: Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol; 2003 Aug;17(4):663-81
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local and regional recurrence of vulval cancer: management dilemmas.
  • Vulval cancer has an incidence of 1-2/100000.
  • Approximately one-third of patients develop recurrent disease usually within the first 2 years following primary treatment.
  • Radical exenterative procedures are considered when the recurrence involves the urethra, bladder, vagina and/or the anorectal canal.
  • Chemoradiation therapy may be used pre-operatively or to palliate the disease.
  • Surgical effort to debulk large-volume groin disease is often unsuccessful and chemoradiation therapy is the cornerstone of treatment.
  • The management of retroperitoneal and distant disease recurrence is generally based on symptom control as radiation therapy and chemotherapy have limited success.
  • Palliative medicine should be integrated early in the management plan both in patients with incurable recurrent disease and in those undergoing potentially curative treatments.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / therapy. Palliative Care / methods. Vulvar Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Hemorrhage / therapy. Humans. Inguinal Canal. Neoadjuvant Therapy. Pelvis. Radiotherapy, Adjuvant. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12965138.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


28. Hoffman KE, Horowitz NS, Russell AH: Healing of vulvo-vaginal radionecrosis following revascularization. Gynecol Oncol; 2007 Jul;106(1):262-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healing of vulvo-vaginal radionecrosis following revascularization.
  • BACKGROUND: Invasive cancers of the vagina and vulva are treated with radiation-based therapy when proximity of the bladder and/or rectum precludes conservative surgical resection.
  • Patient factors affect non-malignant tissue tolerance to radiation exposure.
  • CASE: A smoker with atherosclerotic disease developed tissue necrosis and the worsening of claudication after chemoradiation treatment of locally advanced squamous cell carcinoma of the vulva and vagina.
  • CONCLUSION: Conditions with impaired microvasculature, such as smoking and atherosclerotic disease, are associated with an increased incidence and severity of complications after radiation treatment.
  • Patients undergoing pelvic radiation treatment should be counseled to modify their vascular risk factors.
  • If this fails and patients develop significant radiation necrosis due to compromised arteriole flow, revascularization or stenting may offer important treatment options.
  • [MeSH-major] Radiation Injuries / surgery. Vagina / blood supply. Vulva / blood supply
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Female. Humans. Middle Aged. Necrosis. Radiotherapy / adverse effects. Smoking / adverse effects. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / radiotherapy. Vascular Surgical Procedures / methods. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507081.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Wielgos M, Szymusik I, Banaszek A, Suchonska B, Kaminski P, Gadomska H, Bablok L: Cancer of the urinary bladder neovagina in a patient with Morris' syndrome. Onkologie; 2008 Feb;31(1-2):53-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the urinary bladder neovagina in a patient with Morris' syndrome.
  • BACKGROUND: Vaginal agenesis is a rare condition, therefore the incidence of a malignant transformation in the neovagina is extremely low.
  • CASE REPORT: We report on a 42-year-old patient with Morris' syndrome and urinary bladder neovagina with a history of prolonged infections of the urinary bladder and intertrigo of the perineal region.
  • The biopsy revealed a squamous cell carcinoma arising from the neovagina.
  • The patient underwent combined radio- and chemotherapy and was disqualified from surgical treatment because of the advanced stage of the disease.
  • In addition, urinary bladder does not seem to be a good material for a functional vagina.
  • [MeSH-major] Androgen-Insensitivity Syndrome / surgery. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Postoperative Complications / pathology. Reconstructive Surgical Procedures. Surgical Flaps / pathology. Urinary Bladder / pathology. Vagina / abnormalities. Vagina / surgery. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Neoplasm Invasiveness. Neoplasm Staging. Pelvis / pathology. Radioisotope Teletherapy. Syndrome


30. Uzan C, Vincens E, Balleyguier C, Gouy S, Pautier P, Duvillard P, Haie-Meder C, Morice P: Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy. Int J Gynecol Cancer; 2010 Apr;20(3):379-84
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with incomplete resection after surgery for stage IB2/II cervical carcinoma with chemoradiation therapy.
  • OBJECTIVE: Standard treatment of stage IB2/II cervical carcinoma is chemoradiation therapy.
  • The place of surgery after this treatment is debated, except when there is suspicion of residual disease.
  • (1) stage IB2/II cervical cancer, (2) external radiotherapy (45 Gy) with concomitant chemotherapy followed by uterovaginal brachytherapy (15 Gy), (3) magnetic resonance imaging performed between 3 and 8 weeks after brachytherapy, and (4) completion surgery with incomplete resection of pelvic disease.
  • The locations of the incomplete resection were (some patients had several locations) the parametrium (n = 4), lateral limit of the cervix (n = 4), anterior (n = 2), posterior (n = 3), and vagina (n = 2).
  • One patient had received chemotherapy for metastatic para-aortic nodes.
  • Seven patients died with a median period of 11 months after surgery (range, 3-21 months).
  • CONCLUSIONS: The prognosis is poor when resection is incomplete after chemoradiation therapy in advanced-stage cervical cancer, and further surgery does not seem to improve this outcome.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / therapy. Carcinoma, Squamous Cell / therapy. Hysterectomy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasm, Residual / pathology. Neoplasm, Residual / therapy. Para-Aortic Bodies / pathology. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375801.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Eleutério J Jr, Giraldo PC, Cavalcante DI, Gonçalves AK, Eleutério RM, Giraldo HP: Papillary squamous cell carcinoma of the uterine cervix, high-risk human papilloma virus infection and p16(INK4a) expression: a case report. Acta Cytol; 2009 Mar-Apr;53(2):188-90
Hazardous Substances Data Bank. COUMARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary squamous cell carcinoma of the uterine cervix, high-risk human papilloma virus infection and p16(INK4a) expression: a case report.
  • BACKGROUND: Papillary squamous cell carcioma is rare form of squamous cell carcinoma of the uterine cervix occurring in women in the sixth decade of life and is frequently misdiagnosed as high-grade intraepithelial lesion.
  • CASE: A 58-year-old woman who had 8 gestations (no abortions) and mitral cardiopathy treated with coumarin medication was referred for transvaginal bleeding of 20 days' duration.
  • Specular examination showed an exophytic, easily bleeding lesion occupying all of the uterine cervix and superior third of the vagina.
  • Liquid-based cytology showed squamous cells, mostly basaloid but some bizarre or in fiber, with clearly atypical nuclei.
  • Second-generation hybrid capture for high-risk human papillomavirus was positive, with a viral load of 404 relative light unit/positive control B, and the tumor expressed p16(INK4a).
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Squamous Cell / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Anticoagulants / therapeutic use. Coumarins / therapeutic use. Female. Humans. Middle Aged. Mitral Valve Insufficiency / complications. Mitral Valve Insufficiency / drug therapy. Vaginal Smears


32. Sinha B, Stehman F, Schilder J, Clark L, Cardenes H: Indiana University experience in the management of vaginal cancer. Int J Gynecol Cancer; 2009 May;19(4):686-93
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indiana University experience in the management of vaginal cancer.
  • PURPOSE: To review our institutional experience in the treatment of primary vaginal cancer and identify predictors for outcome, in particular, recurrence rate.
  • MATERIALS AND METHODS: We retrospectively reviewed the charts of 45 patients identified as having primary squamous cell cancer and adenocarcinoma of the vagina and recorded information regarding both patient and tumor characteristics and treatment modalities.
  • Treatment modalities included surgery and radiation with or without chemotherapy (6 patients), radiation alone (30 patients), and chemoradiation (9 patients).
  • RESULTS: The median follow-up time for all surviving patients was 5.8 years (range, 9-146 months).
  • The 5-year overall survival rates by stage were carcinoma in situ with microinvasion and stage I, 92%; stage II, 82%; and stages III and IVA, 20% (P = 0.0005).
  • The 5-year progression-free survival rates by stage were carcinoma in situ and stage I, 92%; stage II, 88%; and stages III and IVA, 30% (P = 0.00049).
  • CONCLUSIONS: Early-stage vaginal cancer can be successfully managed with radiation therapy with excellent rates of local control and survival.
  • Patients with stages III and IV disease have a very poor outcome, and more aggressive therapies need to be investigated.
  • Given the limited number of patients treated with chemotherapy and radiation, no definitive conclusions can be made regarding the impact of combined therapy in the management of this disease.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brachytherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Vaginal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509572.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement